These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 32327617)
1. Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology. Blanco-García E MEDICC Rev; 2020 Jan; 22(1):11-16. PubMed ID: 32327617 [TBL] [Abstract][Full Text] [Related]
2. Business Ethics 101 for the biotech industry. MacDonald C BioDrugs; 2004; 18(2):71-7. PubMed ID: 15046523 [TBL] [Abstract][Full Text] [Related]
3. Paring down the company: the effect of consolidation in the European biotech sector. Bassett P Nat Biotechnol; 2003 Jul; 21(7):829-30. PubMed ID: 12833105 [No Abstract] [Full Text] [Related]
4. Perspective: Biotech funding trends: Insights from entrepreneurs and investors. Gruber AC Biotechnol J; 2009 Aug; 4(8):1102-5. PubMed ID: 19685460 [TBL] [Abstract][Full Text] [Related]
5. New biotech hubs may emerge as industry matures. Basu P Nat Biotechnol; 2003 Oct; 21(10):1123. PubMed ID: 14520385 [No Abstract] [Full Text] [Related]
6. Invention and business performance in the tissue-engineering industry. Pangarkar N; Hutmacher DW Tissue Eng; 2003 Dec; 9(6):1313-22. PubMed ID: 14670118 [TBL] [Abstract][Full Text] [Related]
7. The evolution of the biotechnology industry in Germany. Müller C Trends Biotechnol; 2002 Jul; 20(7):287-90. PubMed ID: 12062972 [TBL] [Abstract][Full Text] [Related]
9. Making it in the biotech business. Gewin V Nature; 2005 May; 435(7038):124-5. PubMed ID: 15875029 [No Abstract] [Full Text] [Related]
10. Much Ado about Something: Cuban Biotech. Editors of MEDICC Review MEDICC Rev; 2016 Jul; 18(3):3. PubMed ID: 27510929 [TBL] [Abstract][Full Text] [Related]
11. Making the biotech IPO work. McNamee L; Ledley F Nat Biotechnol; 2013 Nov; 31(11):969-70. PubMed ID: 24213765 [No Abstract] [Full Text] [Related]
12. Editorial: Biotech in the financial crisis. Jungbauer A Biotechnol J; 2009 Aug; 4(8):1095. PubMed ID: 19685457 [No Abstract] [Full Text] [Related]
13. Biotech venture capital--it's not too late to be early. Klausner A Nat Biotechnol; 2005 Apr; 23(4):417-8. PubMed ID: 15815662 [No Abstract] [Full Text] [Related]
14. Swiss Startup Framework: A Highly Effective Network Supporting the Generation of Emerging Biotech Businesses. Mitchell I; Steiner S; Altorfer M; Suter-Dick L Chimia (Aarau); 2020 Oct; 74(10):765-767. PubMed ID: 33115556 [TBL] [Abstract][Full Text] [Related]
16. Sticking to the knitting: CIHR, innovation and Canadian biotech. Edelson J Healthc Q; 2005; 8(3):65-8. PubMed ID: 16078405 [TBL] [Abstract][Full Text] [Related]
17. Market entry and exit by biotech and device companies funded by venture capital. Burns LR; Housman MG; Robinson CA Health Aff (Millwood); 2009; 28(1):w76-86. PubMed ID: 19049998 [TBL] [Abstract][Full Text] [Related]
18. The evolution of biotechnology and its impact on health care. Evens R; Kaitin K Health Aff (Millwood); 2015 Feb; 34(2):210-9. PubMed ID: 25646100 [TBL] [Abstract][Full Text] [Related]
19. A venture capital view of challenges, opportunities, and innovation in biomedical research. Ratcliffe LT Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935 [TBL] [Abstract][Full Text] [Related]
20. Overcoming the challenges in the pharma/biotech industry. Graul AI; Prous JR Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]